Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06387472 · ClinicalTrials.gov registry record · NA
DermAI to Evaluate Human Factor of Testing
A NA study of Contact Dermatitis, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 151
- Enrollment target
- 1
- Study location
NCT06387472: Completed NA study of Contact Dermatitis, sponsored by Mayo Clinic.
NCT06387472 is a NA study of Contact Dermatitis that has completed, run by Mayo Clinic. The registered enrollment target is 151 participants, above the 102-participant average among 3 other Contact Dermatitis trials with a reported enrollment target (48% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06387472, a NA study of Contact Dermatitis, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 151 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to improve how well remote patch allergy testing works and make sure they are easy and practical for people to use from home.
Primary Outcome
Number of skin patch interpretations using novel AI algorithms analysis to be in concordant with human review interpretation for the classification of regions within the test panel that either were a reaction (reaction grade 1+) or no reaction (grade 0).
Conditions Studied
Interventions
- DEVICE AI algorithm to evaluate photographs of skin test patch regions
- DEVICE Allergen Patch
Study Locations (1)
Florida
- Mayo Clinic in Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2024-05-08 |
| Est. Completion | 2024-12-13 |
| Phase | NA |
What the finished NCT06387472 record still lists
NCT06387472 is an interventional study that assigns participants to a tested intervention. The registered 151 participants enrollment target is mid-sized for trials with a published cap, above the 102-participant average among 3 other Contact Dermatitis trials with a reported enrollment target (48% higher).
The record links to 1 condition, with Contact Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which AI algorithm to evaluate photographs of skin test patch regions is the first listed.
NCT06387472 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06387472 about?
NCT06387472 is a clinical study titled "DermAI to Evaluate Human Factor of Testing". The purpose of this research is to improve how well remote patch allergy testing works and make sure they are easy and practical for people to use from home.
What is the current status of trial NCT06387472?
This trial is currently completed. It is a NA study. The enrollment target is 151 participants. The study started on 2024-05-08. Estimated completion is 2024-12-13.
What conditions does trial NCT06387472 study?
This clinical trial studies the following conditions: Contact Dermatitis.
What interventions are being tested in trial NCT06387472?
The interventions under investigation include: AI algorithm to evaluate photographs of skin test patch regions (DEVICE), Allergen Patch (DEVICE).
Who is sponsoring clinical trial NCT06387472?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06387472 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Contact Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01409161 · 151 participants · Phase 2
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
- NCT04245397 · 151 participants · Phase 1
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
- NCT05761223 · 151 participants · Phase 1
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
- NCT07195656 · 151 participants · NA
Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI